Blood test trial aims to speed up lung cancer treatment decisions
NCT ID NCT04912687
Summary
This study tested whether combining a blood test (liquid biopsy) with traditional tissue analysis could better identify specific genetic changes in patients with advanced non-small cell lung cancer. Researchers enrolled 581 newly diagnosed patients to compare how well each method detected EGFR mutations, which can guide treatment choices. The goal was to see if this combined approach could provide more accurate results and potentially reduce delays in starting targeted therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Lille
Lille, 59037, France
-
CHU Nice-Hopital de Cimiel
Nice, 06000, France
-
CHU Poitiers
Poitiers, 86021, France
-
CHU Strasbourg
Strasbourg, 67091, France
-
CHU de Rennes - Hopital Pontchaillou
Rennes, 35033, France
-
Hospices Civils de Lyon
Lyon, 69002, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Curie
Paris, 75248, France
-
Institut de Cancérologie de l'Ouest - Site Paul Papin
Angers, 49000, France
Conditions
Explore the condition pages connected to this study.